Around 75% of patients with breast cancer have tumors expressing estrogen receptor α (ER) and are offered adjuvant endocrine therapy for 5–10 years, which reduces the risk of recurrence by almost 50% and the mortality by up to 30%3. This evidence concerns the gene ESR1 and breast carcinoma.